Abion Signs MOU with DeepBio for AI-Based Companion Diagnostics and Clinical Development

ABION announced on the 5th that it has signed a Memorandum of Understanding (MOU) with DeepBio, an AI-based digital pathology specialist company. Through this agreement, AI technology will be utilized in cancer diagnosis services and clinical trials for cancer drug development.

ABION will share clinical data from its pipelines, including Babamakeup (ABN401), and collaborate on developing in vitro diagnostics and companion diagnostic services. DeepBio plans to apply its AI-based 'c-MET immunohistochemistry (IHC) reading service' to ABION's new drug development and clinical trials. The two companies have been discussing this collaboration since 2020, and it was formalized as ABION began combination clinical trials.

Choi Jun-young, Vice President of ABION, stated, "We will first integrate DeepBio's AI-based IHC reading technology into the combination clinical trials of Babamakeup and Lazertinib. We expect this to enhance the competitiveness of our new drug pipeline."

Kim Sun-woo, CEO of DeepBio, said, "A key challenge in new drug development clinical trials is clearly identifying patient groups that are highly suitable for the new drug. Through this MOU, we hope that our DeepCDx solution will improve patient enrollment and selection processes, thereby contributing to ABION's future drug development."

ABION is currently conducting combination clinical trials of Babamakeup and Lazertinib, aiming to register the first patient within the year. On the 20th (local time), the U.S. Food and Drug Administration (FDA) approved the combination therapy of Lazertinib and Livrivant, which is expected to benefit ABION.

ABION plans to continue collaborating with highly skilled diagnostic companies to improve cancer diagnosis accuracy, increase the success rate of new drug clinical development, and enhance pipeline value. The strategy is to expand AI integration across various indications and accelerate clinical trials for each therapeutic agent.

Meanwhile, DeepBio is a company that developed the world's first AI-based prostate cancer severity classification software and ranks among the top 10 in the digital pathology field. Its flagship solution, the prostate cancer analysis AI 'DeepDx Prostate,' has obtained European certification (CE-IVD). Based on its AI capabilities, DeepBio focuses on developing companion diagnostic services and provides customized solutions to enhance the precision and efficacy of pharmaceutical companies' new drug development pipelines.